BI 505

Drug Profile

BI 505

Alternative Names: BI-505

Latest Information Update: 23 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioInvent International
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 12 Dec 2016 BioInvent International terminates a phase I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA due to a full clinical hold by the US FDA (NCT02756728)
  • 08 Nov 2016 The US FDA places a full clinical hold on a phase-II clinical trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA
  • 01 Nov 2016 Suspended - Phase-II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top